Valontan

Quick links to important sections

Valontan

Method of action: Antiemetic

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Valontan

The following section provides a definitive overview of the identity, composition, and general purpose of Valontan (Dimenhydrinate), a synthetic medicinal preparation primarily recognized for its application in travel-related symptoms.

Property Description
Active ingredient Dimenhydrinate
Form Coated Tablets, Suppositories, Injectable solution
Pharmacological class Antiemetic Agents, First-Generation H1-Antihistamines
Common use Prevention and relief of Motion sickness and associated symptoms
Origin Synthetic (chemically synthesized molecule)

What Type of Medicine is Valontan?

Valontan is an antiemetic agent that belongs to the first-generation H1-antihistamine pharmacological class, targeting signals in the central nervous system that cause dizziness and nausea. Its core active ingredient is Dimenhydrinate, which is a chemically synthesized molecule. The classification of Dimenhydrinate as an effective antiemetic is clinically recognized for its action against motion-related symptoms. Its action is primarily centered on blocking histamine receptors located in the vestibular system and the brain’s chemoreceptor trigger zone (CTZ), which makes it particularly effective against motion-induced symptoms rather than strictly allergic reactions.

Valontan's Composition and Available Forms

The active substance, Dimenhydrinate, is unique in that it is structurally a combination drug, specifically a theoclate salt formed from two components: Diphenhydramine (the potent anti-nausea agent) and 8-chlorotheophylline (a mild stimulant). This internal composition provides a differentiating factor compared to pure Diphenhydramine products, as the addition of the mild stimulant is intended to temper the sedative effect. The drug is consistently provided in coated tablets for oral use, though suppositories and specialized injectable solution formulations also exist.

General Purpose: What Does Valontan Help With?

The general therapeutic purpose of Valontan is to stabilize the sensory processes disturbed by movement, thereby effectively alleviating severe nausea, vomiting, and feelings of vertigo associated with travel. The medication helps by reducing the conflicting or excessive sensory input from the inner ear's balance mechanism. This function is why it is typically used for common situations like preventing car sickness on long journeys.

Regulatory References

  1. Dimenhydrinate: MedlinePlus Drug Information

What side effects are possible with Valontan?

Possible Side Effects and Safety Information

The safety profile of Valontan (Dimenhydrinate) is primarily characterized by effects related to its action on the Central Nervous System (CNS) and its anticholinergic properties, as documented in official regulatory labeling.


Adverse Reaction Classification

Side effects are officially classified by their frequency of occurrence. The most frequent and expected reactions are categorized as Very Common (ge 1/10 patients), which includes sedation and drowsiness. Adverse reactions categorized as Common (ge 1/100 to < 1/10 patients) typically include headache, dizziness, and dry mouth. Reactions are also classified into System-Organ Classes, with frequent reports affecting the Nervous System and Gastrointestinal System.

Classification Aspect Key Documented Adverse Reactions
Very Common Sedation, Drowsiness
Common Headache, Dizziness, Dry mouth, Constipation
Not Known (Frequency) Tachycardia, Blurred vision, Hypersensitivity reactions

Population and Duration Safety Notes

Official documents highlight safety considerations for specific groups. Older Adults may exhibit increased sensitivity to adverse effects, particularly dizziness, confusion, and urinary retention, which are associated with the drug's anticholinergic activity. The onset of drowsiness may be more pronounced at the start of treatment. Furthermore, caution is warranted in patients with pre-existing conditions sensitive to anticholinergic effects, such as narrow-angle glaucoma or prostatic hypertrophy.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory information for Valontan (Dimenhydrinate) defines overdose through a set of documented manifestations that require immediate medical attention.

Category Official Regulatory Statement
Documented Overdose Presentations Symptoms of the Anticholinergic Syndrome, including fixed and dilated pupils, hyperpyrexia (fever), flushed face, and dry mouth. CNS effects include agitation, delirium, and hallucinations.
Physiological Systems Affected Central Nervous System (CNS) and Cardiovascular System.
Severe Outcomes Convulsions, profound coma, and major cardiac arrhythmias that can lead to circulatory collapse are explicitly documented.
Population-Specific Notes Pediatric patients are noted to be prone to paradoxical stimulation (excitation) and heightened severity, increasing the risk of seizures and severe outcomes.

Immediate Actions and Required Monitoring

The official instruction is to seek immediate medical attention for any suspected overdose. Emergency services must be contacted immediately if the patient is unresponsive or exhibits a seizure, collapse, or trouble breathing.

Official Overdose Statements:

  • The documented management is symptomatic and supportive, as no specific antidote is known.
  • ECG monitoring and continuous observation of vital signs are required procedural steps to assess and manage the documented cardiotoxicity risk.
  • The severity is classified as potentially life-threatening due to cardioneurological risk.

This profile, derived strictly from regulatory documents, defines the clinical signs that trigger emergency response and outlines the mandated supportive procedures.

Therapeutic Uses of Valontan

Uses and Therapeutic Benefits of Valontan (Dimenhydrinate)

Valontan, which contains dimenhydrinate, is commonly used to help with symptoms related to heightened physiological activity and may support general well-being during symptomatic phases. This medication is applied across domains where additional symptomatic support is needed, particularly in clinical settings that involve acute or unstable symptom patterns.

The medicine is applied in addressing symptomatic assistance for nausea, vomiting, and vertigo. This is considered relevant in conditions where functional stability becomes affected, such as motion sickness, Menière’s disease, and other labyrinthine disturbances. Symptomatic assistance provided may help patients cope more steadily with symptom fluctuations, contributing to improved comfort during periods of heightened symptoms.

Its application may assist with easing the overall symptom burden applied during phases of increased distress or discomfort. The supportive relief provided may help maintain a sense of stability when symptoms are more noticeable. This supportive relief is often used when symptoms intensify and **may assist with maintaining functional stability.


Quick Fact: Symptomatic Assistance for Dizziness and Nausea

Quick Fact: Symptomatic Assistance for Dizziness and Nausea


Regulatory References

  1. Health Canada Product Monograph

Eligibility and Restrictions for Use

Who Can and Cannot Use Valontan? (Dimenhydrinate)

Official regulatory documents establish specific population rules regarding the use of Valontan (Dimenhydrinate). These rules define both absolute prohibitions and conditions where special caution is required.

Contraindicated Populations

Valontan is contraindicated and must not be used by patients with a known hypersensitivity to dimenhydrinate or similar antihistamines, or by patients with Porphyria. Use is also strictly contraindicated in neonates, premature infants, and generally in children younger than 2 years of age.

Age and Conditional Restrictions

While use is approved for adults and children aged 2 to 12 years, caution is required for the older adult population due to increased susceptibility to effects. The medicine must be used with caution in patients with conditions that may be aggravated by anticholinergic effects, such as narrow-angle glaucoma, prostatic hypertrophy, or pyloroduodenal obstruction.

Organ Function and Pregnancy Status

Patients with hepatic impairment must use the drug with caution. Those with renal impairment may require a dose adjustment. Valontan is FDA Pregnancy Category B, meaning use is recommended only if clearly needed. For nursing mothers, official labeling states that a decision must be made to either discontinue the drug or discontinue nursing.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Valontan (Dimenhydrinate) is defined by its officially documented effects on the central nervous system (CNS) and its anticholinergic properties.


Official Interaction Statements

Category Interacting Agents and Restriction
Contraindicated Combinations Monoamine Oxidase Inhibitors (MAOIs), which require a 14-day separation period, and specific Class I and Class III Antiarrhythmics (e.g., Amiodarone, Quinidine) due to the risk of QTc prolongation.
CNS Depressant Potentiation Alcohol, opioid analgesics, sedatives, and hypnotics are documented to result in an additive sedative effect. Regulatory labels require a pre-emptive dose reduction of co-administered Narcotic Analgesics and Barbiturates.
Anticholinergic Reinforcement Co-administration with other anticholinergic agents, such as Tricyclic Antidepressants (TCAs) and Antipsychotics, can produce additive effects.
Masking Effect Use with Ototoxic Drugs, including Aminoglycoside Antibiotics, is cautioned because Dimenhydrinate is documented to mask the early symptoms of inner ear damage.
Pharmacokinetic Note Dimenhydrinate is noted as an inhibitor of the enzyme CYP2D6, indicating a potential interaction with drugs primarily metabolized by this pathway.

Interaction constraints note that Elderly Patients may exhibit increased susceptibility to the CNS and anticholinergic effects resulting from these combinations. No known interactions with common foods are documented in official sources.

Mechanism of Action

Valontan is a selective non-competitive antagonist of the L-type calcium channel (LTCC). This interaction is concentrated primarily within bone tissue, specifically targeting the membrane receptors of osteoclasts. The LTCC antagonism induces a concentration-dependent decrease in the influx of extracellular calcium into the osteoclast cytoplasm. The resulting intracellular environment alters downstream signaling cascades necessary for osteoclast activation and function. This modification of signaling, which includes an effect on intracellular calcium release from stores, ultimately leads to a direct reduction in the acid secretion and enzymatic activity required for the breakdown of bone matrix. This cellular inhibition results in a system-level decrease in osteoclast-mediated bone resorption. Additionally, the compound is known to modulate the RANKL/RANK/OPG signaling axis, further influencing the overall balance of bone cell differentiation and survival.

Dosage and Administration Information

The administration of Valontan (Dimenhydrinate) follows specific protocols established in regulatory labeling concerning the route, dose, and timing. The medicine is available for administration via the oral route (tablets, solutions), the rectal route (suppositories), and the parenteral routes, which include intramuscular (IM) and intravenous (IV) injection.

For preventive use against motion-related symptoms, the initial dose must be administered 30 minutes to 1 hour prior to the activity or exposure to motion. Subsequent doses for continuous symptomatic management are administered based on the minimum required interval.

Standardized Dosing Regimens

Population Standard Dosing Range Maximum Daily Limit
Adults (and 12 yrs) 50 mg to 100 mg every 4 to 6 hours 400 mg
Children (6 to <12 yrs) 25 mg to 50 mg every 6 to 8 hours 150 mg

The injectable form is reserved for use when oral administration is impractical. The intravenous dose of 50 mg requires mandatory dilution in a minimum of 10 mL of appropriate solution and must be administered slowly over at least two minutes to adhere to the labeled administration rate. Oral forms may be taken with or without food. Administration is primarily for short-term, as-needed (prn) use.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Valontan contains dimenhydrinate, an antihistamine substance. Its primary role in clinical research involves the prevention and treatment of symptoms associated with motion sickness, including nausea, vomiting, and dizziness.

Research has explored whether the medication is associated with reductions in these acute symptoms. Studies have included analysis of the safety profile in adult populations for its approved indications.


Study Findings by Condition

Motion Sickness and Vertigo

Controlled clinical trials on dimenhydrinate (the active ingredient in Valontan) have historically focused on its use in conditions related to inner ear imbalances (labyrinthine disorders) and motion-induced sickness.

Studies compared outcomes associated with the agent to those of placebo or other single-agent treatments. The evidence primarily focuses on the acute administration of the drug and the time frame of symptom reduction following a single dose. Results were generally observed to be consistent with its classification as an antiemetic and antihistamine agent.

Safety Profile

Studies have included analysis of the safety profile in adults. Common adverse events examined across research reports include drowsiness, dry mouth, blurred vision, and dizziness. Researchers also assessed the drug's use in individuals with certain pre-existing conditions, such as glaucoma or prostate hypertrophy, noting the potential for existing symptoms to be exacerbated. Research reports evaluated potential interactions with other central nervous system depressants, such as alcohol or sedatives.

Frequently Asked Questions (FAQ)

Common questions about Valontan (FAQ)


Q: How quickly does Valontan usually start working?

According to the official product information, Valontan is typically recommended to be taken 30 minutes to 1 hour before an activity to help prevent motion sickness symptoms. Once administered, the duration of effect for a single oral dose is generally indicated to be between four to eight hours. This reflects the timeframe for which the drug's effects are present.

Q: Can Valontan cause stomach upset?

Official documents indicate that common gastrointestinal effects include dry mouth and constipation. While the frequency is not always established in labeling, reports of other gastrointestinal issues, such as nausea or epigastric distress (stomach discomfort), have been noted in safety summaries.

Q: Can Valontan affect my sleep?

The most frequent effect of Valontan on the central nervous system is drowsiness and sedation, which can influence the ability to stay awake. However, official safety information also notes that other effects, such as insomnia (difficulty sleeping), nervousness, or restlessness, have also been reported.

Q: Does Valontan interact with over-the-counter cold medicines?

Regulatory documents caution that Valontan should be used carefully with any other medicine that results in drowsiness or has anticholinergic effects. Many over-the-counter cold and cough medicines fall into these categories and could potentially result in an additive sedative effect when taken together.

Q: Is it safe to use Valontan with common blood pressure medications?

Official labeling indicates that Valontan is contraindicated with certain Class I and Class III Antiarrhythmic medicines. Regulatory documents indicate that caution is required when combining Valontan with some blood pressure medications, such as calcium channel blockers. These combinations may lead to additive effects in lowering blood pressure or increasing the risk of QTc prolongation, which is a heart rhythm concern.

Q: Can I drive while taking Valontan?

Regulatory warnings explicitly state that marked drowsiness may occur as a result of using this medication. The presence of drowsiness means that caution is required when operating a vehicle or heavy machinery. This caution is noted until an individual understands how the drug specifically affects their alertness and coordination.

Q: Are there any specific warning signs I should look for when starting Valontan?

Official safety information specifies signs of an allergic reaction (like hives or swelling) as reasons to seek care. Immediate attention by a healthcare provider is noted as necessary if severe effects occur, including excessive drowsiness, blurred vision or eye pain, or painful or difficult urination. These may indicate a serious adverse effect.

Q: Is Valontan recommended for people with a history of heart conditions?

The drug’s labeling states that caution is required in individuals who have certain pre-existing conditions that may be aggravated by its anticholinergic effects. This cautionary group includes patients with conditions like cardiac arrhythmias (irregular heartbeat). Additionally, the drug is specifically contraindicated with certain antiarrhythmic medications.

Q: How does the mechanism of Valontan compare to older drugs for the same condition?

Valontan’s active ingredient, Dimenhydrinate, is structurally a unique combination drug. It consists of the anti-nausea agent Diphenhydramine and a mild stimulant component. This formulation contains a mild stimulant component that is a differentiating factor from pure Diphenhydramine products, and its purpose is noted in regulatory sources as one way to address sedation.

Q: Is it possible to become tolerant to the effects of Valontan over time?

Official monographs indicate that a person can develop tolerance to the central nervous system (CNS) depressant effects of the medication after a few days of use. Furthermore, regulatory documentation notes that a decrease in the drug's effectiveness may be observed when used for prolonged periods of time.

Q: What are the reasons someone might be taken off Valontan?

Regulatory information highlights that a patient may be taken off Valontan if they show a known hypersensitivity to the drug or have conditions such as Porphyria. Discontinuation may also be necessary due to the development of a serious adverse effect or if the patient requires treatment with a contraindicated interacting medication.

Q: What is the biggest misunderstanding people have about Valontan?

The role of Valontan is sometimes misunderstood as solely an anti-allergy medication. However, official information clarifies that its primary effectiveness in motion sickness stems from blocking histamine receptors located specifically in the vestibular system of the inner ear and the brain's chemoreceptor trigger zone. This specific action helps stabilize sensory processes disturbed by motion.

How should Valontan be stored and disposed of?

How to Store and Dispose of Valontan (Dimenhydrinate)

Storage and disposal of Valontan must adhere to official regulatory requirements to maintain product stability and safety.

Official Storage Requirements

Valontan (dimenhydrinate) tablets must be stored at Controlled Room Temperature (CRT), which is between 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. The medicine must be kept in its original container and protected from moisture.

Disposal and Child Safety

All medicine must be stored out of the sight and reach of children.

Unused or expired Valontan should be prepared for disposal in the household trash by mixing it with an unappealing substance like dirt or coffee grounds. The product must not be disposed of in wastewater (e.g., flushed down the toilet or drain).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Valontan found in:

A-Z Index: